Berberine for Type 2 Diabetes
Verdict: Published with Warning
Across 5 PubMed studies, the evidence for Berberine in Type 2 Diabetes grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.58
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
80%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.581
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (5)L2 · primary research & systematic reviews
Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis
Finding: Berberine alone reduced FPG (MD -0.59 mmol/L, p=0.048) and 2hPBG (MD -1.57 mmol/L, p<0.01); combined with hypoglycemic drugs: HbA1c MD -0.69% and FPG MD -0.99 mmol/L (both p<0.01).
View on PubMed The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Finding: Berberine significantly reduced HbA1c (MD -0.73%, 95% CI -0.97 to -0.51), FPG (MD -0.86 mmol/L, 95% CI -1.10 to -0.62), and 2hPG (MD -1.26 mmol/L, 95% CI -1.64 to -0.89).
View on PubMed Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis
Finding: Berberine significantly reduced FPG (WMD -0.82 mmol/L, 95% CI -0.95 to -0.70), HbA1c (WMD -0.63%, 95% CI -0.72 to -0.53), and 2hPBG (WMD -1.16 mmol/L, 95% CI -1.36 to -0.96) with no significant increase in hypoglycemia risk.
View on PubMed The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials
Finding: Berberine reduced HbA1c (ESWMD -0.57, 95% CI -0.68 to -0.46) and insulin (ESWMD -1.00, 95% CI -1.70 to -0.30); conclusions inconsistent across some sub-analyses.
View on PubMed Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
Finding: HTD1801 1000 mg BID reduced HbA1c by -0.7% (95% CI -1.10 to -0.35, p<0.001) and FPG by -18.4 mg/dL vs placebo; 500 mg also significant (HbA1c -0.4%, p=0.04).
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Cautious
BERBERINE HCL（鹽酸小檗鹼）含量 100mg，適應症：痢疾、胃加答兒、吐瀉、腹瀉、軟便、腹痛引起之下痢，消化不良性下痢。藥品類別：醫師藥師藥劑生指示藥品。不得連續服用一星期以上。（衛署藥製字第014055號「東洲」喜力安膠囊仿單） source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Berberine may improve blood sugar measures such as fasting glucose and hemoglobin A1c (HbA1c) in those with type 2 diabetes, and by some measures may work about as well as the commonly prescribed oral diabetes medication metformin. source↗
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Against